Start
•
Completion

Psilocybin in Functional Neurological Disorder (PsiFUND)

Not yet recruitingRegisteredCTG

This open-label trial (n=24) aims to investigate the impact of a single dose of psilocybin (25mg), administered with therapeutic support, on the default mode network (DMN) in individuals with Functional Neurological Disorder (FND).

Details

Open-label, single-group basic-science study administering a single 25 mg oral dose of psilocybin with therapeutic support to 24 adults with FND, with pre- and post-dose fMRI.

Primary outcome is change in default mode network connectivity on fMRI; additional assessments include CGI-S, safety/tolerability and ability to tolerate MRI procedures.

Topics:Neuroimaging & Brain Measures

Registry

Registry linkNCT05723276